Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck KGaA
Biotech
Merck KGaA drops pipeline asset from SpringWorks buyout
Merck KGaA is no longer pursuing clinical-stage candidates obtained through its acquisition of SpringWorks, which centered on approved drugs.
Will Maddox
Mar 5, 2026 4:33pm
Sanofi's stunning CEO switch—Chutes & Ladders
Feb 13, 2026 8:30am
Fierce Pharma
Sanofi ousts Paul Hudson for Merck KGaA chief after 'bumpy ride'
Feb 12, 2026 4:26am
Merck teams up with British medtech Calla Lily
Feb 10, 2026 9:40am
Guardant Health gets FDA nod to expand test for colon cancer
Jan 26, 2026 8:15am
Merck KGaA becomes latest partner for Flagship’s Valo Health
Nov 20, 2025 6:30am
